Clinical trial · Observational
18F-Clofarabine PET/CT in Imaging Cancer Patients Before and After Interventions
The Biodistribution of [18F]-Clofarabine in Cancer Patients Before and After Interventions That Increase the Activity of Deoxycytidine Kinase
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): slow accrual
Summary
Brief summary (as posted)
This clinical trial studies 18F-clofarabine positron emission tomography (PET)/computed tomography (CT) in imaging patients with cancer before and after treatment with a therapy that activates the patient's immune system (immunotherapy). PET/CT scans give detailed pictures of areas inside the body. 18F-clofarabine is a drug that contains a radioactive substance that is taken up by cells expressing deoxycytidine kinase (dCK), which is highly expressed in activated immune cells, making them light up during PET/CT scans. Doctors also want to know how 18F-clofarabine is distributed throughout the body before and after treatment with immunotherapies.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Malignant Neoplasm | Malignant Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Computed Tomography | Procedure | — | UNRESOLVED |
| Fluorine F 18 Clofarabine | Radiation | — | UNRESOLVED |
| Positron Emission Tomography | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Basic science (18F-clofarabine biodistribution)
- description
- Patients receive 18F-clofarabine IV and undergo PET/CT scan at baseline and 2-4 weeks after completion of immunotherapy.
- interventionNames
- Procedure: Computed Tomography
- Radiation: Fluorine F 18 Clofarabine
- Procedure: Positron Emission Tomography
Primary outcomes (2)
- measure
- 18F-clofarabine concentration in cancer tissue
- timeFrame
- Up to 4 weeks
- measure
- Change in 18F-clofarabine biodistribution
- timeFrame
- Baseline to up to 4 weeks
- description
- For the biodistribution studies, regions of interest will be drawn on images of liver, kidney, bladder, heart, lung and blood pool to obtain regional activity count rates. Standardized uptake values (SUV = count activity per ml within region of interest (MBq-1)/(injected dose \[MBq\]/body weight \[kgx1000\]) will be calculated for different organs and for regions of tumor. Further, regional target to background count activity ratios will be established.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Must be able to tolerate PET/CT (i.e. not claustrophobic and able to remain supine) * No restrictions based on gender or racial/ethnic background Exclusion Criteria: * Women of childbearing age will have to undergo a pregnancy test that will be provided free of charge
References
Publications (0)
Data not yet available